Matthew W. McClure - 07 Jul 2022 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Chief Medical Officer
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Matthew W. McClure
Issuer symbol
ALGS
Transactions as of
07 Jul 2022
Net transactions value
$0
Form type
4
Filing time
11 Jul 2022, 16:15:52 UTC
Previous filing
06 May 2022
Next filing
17 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +46,000 $0.000000 46,000 07 Jul 2022 Common Stock 46,000 $1.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.